Five years after its launch, virtual biotech Aesrx LLC has advanced a small molecule anti-sickling agent into a Phase II trial in patients with sickle cell disease (SCD) – and done so without a venture capital round. If the compound proves its mettle, the company could become the first to market a treatment that directly blocks cell sickling rather than seeking simply to reduce the frequency of sickle cell crises.